Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175
Guardant Health
Guardant Health GH | 0.00 |
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:
GH) with a Overweight and raises the price target from $130 to $175.
